Adjuvantix is an early-stage biopharmaceutical company, focused on the development of rational means to effectively and safely enhance the immune response to prophylactic and therapeutic vaccines. The Company was formed in 1999, to exploit research emanating from Dr Andrew Heath's lab within the Infection and Immunity Group at Sheffield University. Dr Heath serves as Adjuvantix' Chief Scientific Officer.

WRTSF has been supporting Adjuvantix since 2000.

For further information please contact: Dr Andy Heath on +44 (0)114 271 3516; a.w.heath@sheffield.ac.uk

www.adjuvantix.co.uk